29.96
price down icon0.10%   -0.03
after-market 시간 외 거래: 30.33 0.37 +1.23%
loading
전일 마감가:
$29.99
열려 있는:
$30.12
하루 거래량:
1.64M
Relative Volume:
1.80
시가총액:
$3.10B
수익:
$4.72M
순이익/손실:
$-277.91M
주가수익비율:
-8.0322
EPS:
-3.73
순현금흐름:
$-203.56M
1주 성능:
-0.66%
1개월 성능:
+1.56%
6개월 성능:
-42.22%
1년 성능:
-31.08%
1일 변동 폭
Value
$29.59
$30.85
1주일 범위
Value
$29.59
$31.44
52주 변동 폭
Value
$24.10
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
명칭
Crinetics Pharmaceuticals Inc
Name
전화
858-450-6464
Name
주소
6055 LUSK BLVD., SAN DIEGO, CA
Name
직원
437
Name
트위터
@Crinetics
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
CRNX's Discussions on Twitter

CRNX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CRNX
Crinetics Pharmaceuticals Inc
29.96 3.10B 4.72M -277.91M -203.56M -3.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-25 개시 Stifel Buy
2025-02-11 개시 TD Cowen Buy
2025-02-04 개시 Wolfe Research Peer Perform
2025-01-22 업그레이드 Jefferies Hold → Buy
2024-03-06 개시 Citigroup Buy
2024-01-16 개시 Morgan Stanley Overweight
2023-12-21 개시 Jefferies Hold
2023-11-20 재개 JP Morgan Overweight
2023-10-24 재개 Cantor Fitzgerald Overweight
2023-08-31 개시 Oppenheimer Outperform
2023-04-24 개시 Piper Sandler Overweight
2023-03-30 개시 Robert W. Baird Outperform
2021-11-30 개시 JMP Securities Mkt Outperform
2021-11-23 개시 Evercore ISI Outperform
2021-06-18 업그레이드 JP Morgan Neutral → Overweight
2019-12-23 개시 ROTH Capital Buy
2019-02-14 개시 H.C. Wainwright Buy
2018-08-13 개시 JP Morgan Neutral
2018-08-13 개시 Leerink Partners Outperform
2018-08-13 개시 Piper Jaffray Overweight
모두보기

Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스

pulisher
Jun 18, 2025

Trading (CRNX) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 16, 2025

Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug - Seeking Alpha

Jun 16, 2025
pulisher
Jun 14, 2025

Rhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Crinetics Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Research Analysts Offer Predictions for CRNX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CRNX Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView

Jun 10, 2025
pulisher
Jun 05, 2025

(CRNX) Trading Report - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 05, 2025

Two Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jun 05, 2025
pulisher
Jun 02, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Jane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Thinking Of Buying Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Stock? Here Is What You Should Know - Stocksregister

May 31, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Crinetics stock Buy rating, $81 target By Investing.com - Investing.com Canada

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Crinetics stock Buy rating, $81 target - Investing.com India

May 30, 2025
pulisher
May 26, 2025

(CRNX) Investment Report - news.stocktradersdaily.com

May 26, 2025
pulisher
May 26, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 23, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 | CRNX Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Bank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

May 23, 2025
pulisher
May 23, 2025

BNP Paribas Financial Markets Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

May 23, 2025
pulisher
May 23, 2025

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 - Yahoo Finance

May 23, 2025
pulisher
May 22, 2025

Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com

May 22, 2025
pulisher
May 22, 2025

Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation? - Yahoo Finance

May 22, 2025
pulisher
May 15, 2025

CRNX Achieves FDA Orphan Drug Status for Paltusotine in Carcinoi - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? - MSN

May 15, 2025
pulisher
May 15, 2025

Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - The Manila Times

May 15, 2025
pulisher
May 15, 2025

New Clinical Data: Oral Drug Paltusotine Could Replace Injectable Acromegaly TreatmentsKey AACE 2025 Findings - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Analysts Set Expectations for CRNX FY2025 Earnings - Defense World

May 15, 2025
pulisher
May 13, 2025

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 13, 2025
pulisher
May 10, 2025

Crinetics Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks

May 10, 2025
pulisher
May 10, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 09, 2025

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 09, 2025
pulisher
May 09, 2025

Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges - TipRanks

May 09, 2025
pulisher
May 09, 2025

Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and Pivotal Launches on the Horizon - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Crinetics Pharma stock rises after Q1 2025 results - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Crinetics (CRNX) Exceeds Revenue Expectations, Advances Key Proj - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Crinetics Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $0.4M, EPS Misses at -$1.04 - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Crinetics Pharmaceuticals Reports Progress on Paltusotine NDA and Atumelnant Phase 3 Study Amid Strong Financial Position - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 08, 2025
pulisher
May 08, 2025

11 Stocks That Will Bounce Back According to Analysts - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Viracta Therapeutics (NASDAQ:VIRX) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) Head-To-Head Review - Defense World

May 08, 2025
pulisher
May 08, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

May 08, 2025
pulisher
May 07, 2025

What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Closing Figures: Crinetics Pharmaceuticals Inc (CRNX)’s Negative Finish at 30.52, Down -9.30 - DWinneX

May 07, 2025

Crinetics Pharmaceuticals Inc (CRNX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Betz Stephen F.
Chief Scientific Officer
Jun 12 '25
Sale
32.23
97,483
3,141,877
99,713
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
자본화:     |  볼륨(24시간):